RandyW Posted June 5, 2008 Share Posted June 5, 2008 Among the data emerging at this year's American Society of Clinical Oncology meeting in Chicago were results showing that a combination treatment regimen of Celgene Corp.'s Revlimid (lenalidomide) and Millennium Pharmaceuticals' Velcade (bortezomib), along with dexamethasone, yielded a complete response rate of 35 percent and an overall response rate of 100 percent in newly diagnosed myeloma patients. For Full article click here Its Kinda Long so............ http://www.tmcnet.com/usubmit/2008/06/02/3477305.htm EDITED AND FXED Quote Link to comment Share on other sites More sharing options...
CaroleHammett Posted June 5, 2008 Share Posted June 5, 2008 Hi, Randy and thanks for the posting. When I hit your link, however, it took me to a pop-up (advertising) instead of article so I did a search and found the article at: http://www.tmcnet.com/usubmit/2008/06/02/3477305.htm Thanks again... Carole Life is a Terminal Condition Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.